SYO-2101 / Samyang Group - LARVOL DELTA

Samyang Holdings Strengthens Pharmaceutical Business from CDMO to New Drug Development [Google translation] (Medipana) - "Samyang Holdings is pushing ahead with its pharmaceutical business, including expanding its anticancer CDMO plant and receiving approval for phase 1 clinical trials for its pipeline for the first time in the past three years. Samyang Holdings received approval from the Ministry of Food and Drug Safety on the 12th for phase 1 clinical trials to evaluate the pharmacodynamic characteristics of its own pipelines, 'SYO-2101' and 'SYO-2101R'. According to the Pharmaceutical Safety Country on the 13th, this clinical trial by Samyang Holdings is the first to receive approval in the past three years."

New P1 trial • Hematological Malignancies • Myelofibrosis • Oncology